# Senza5 CART5

Source: https://onco.cc/drugs/viper-101/  
OnCo record `viper-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Senza5 CART5 is an experimental autologous CAR-T cell therapy from Vittoria Biotherapeutics, in phase 1 trials for T-cell non-Hodgkin lymphoma.

## Summary

Senza5 CART5 (VIPER-101) is an autologous CAR-T cell therapy (gene-edited, dual-population) from Vittoria Biotherapeutics, with University of Pennsylvania as partner. A gene-edited autologous CD5-directed CAR-T product made of two engineered cell populations, CD5-knockout cells and CD5-knockout CART5 cells. Its furthest stage is phase 1, for T-cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06420089 recruiting; long-term follow-up study NCT07683897 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: VIPER-101
- Tags: pipeline; ctgov-ingest
- Code: VIPER-101
- Modality: Autologous CAR-T cell therapy (gene-edited, dual-population)
- Mechanism: A gene-edited autologous CD5-directed CAR-T product made of two engineered cell populations, CD5-knockout cells and CD5-knockout CART5 cells.

## Sources

- Vittoria Biotherapeutics: vittoriabio.com: https://vittoriabio.com/pipeline/
- Vittoria Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06420089
- ClinicalTrials.gov: trials of VIPER-101: https://clinicaltrials.gov/search?intr=VIPER-101

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Vittoria Biotherapeutics](https://onco.cc/companies/vittoria-biotherapeutics/)
- trials: [A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials](https://onco.cc/trials/nct07683897/), [CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)](https://onco.cc/trials/nct06420089/)

---
JSON: https://onco.cc/api/v1/entities/viper-101.json